Viewing nowZadiglim Tablet 25 Milligrams (Empagliflozin 2L-Proline)
Empagliflozin 2L-Proline 37.8mg
Tablet · Prescription medication
Mothers Pharmaceutical Co., Ltd.

MFDS item code 202502963 · Approved 2025.11.17
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used to assist in blood sugar control for adult patients with type 2 diabetes. It has a complementary effect in relation to basic dietary therapy and exercise therapy and can be administered either alone or in combination with other medications. Special attention is paid to patients with cardiovascular disease among those whose blood sugar is not adequately controlled. Before taking, one should refer to clinical trial information provided by professionals to confirm safety and efficacy. This medication helps improve blood sugar control and aids in the treatment of type 2 diabetes.
The recommended dose of this drug is 10 mg once daily, as monotherapy or as add-on combination therapy with other glucose-lowering agents such as insulin. If 10 mg of this drug is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this drug is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This drug may be taken with or without food. Swallow the tablet whole. If you miss a dose of this drug, take it as soon as you remember. Do not take a double dose in one day. Special populations •Patients with renal impairment This drug is not recommended for improving glycemic control in patients with an estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2. No dose adjustment is necessary in patients with an estimated glomerular filtration rate of 45 ml/min/1.73m2 or higher. Do not use this drug in patients with end-stage renal disease (ESRD) or who are on dialysis, as efficacy is not expected in these patients. •Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. This drug is not recommended in patients with severe hepatic impairment, as it has not been studied in these patients. •Elderly patients No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older (see Precautions for Use, section 4. General Precautions).
This medication should not be used in patients with hypersensitivity to the active ingredient or any of its components, in patients with type 1 diabetes, and in certain genetically predisposed lactose-intolerant patients. Patients with impaired kidney function must regularly assess their renal function before administering this drug, and it is not recommended for patients with end-stage renal disease or those undergoing dialysis. There is a risk of hypoglycemia when used in conjunction with insulin or insulin secretagogues, so dosage adjustment may be necessary when used with these medications. During treatment, adverse reactions such as hypoglycemia, genital infections, increased urination, urinary tract infections, and decreased fluid volume may occur, so caution is advised. Particularly, serious metabolic abnormalities such as ketoacidosis may occur; thus, if nausea, vomiting, abdominal pain, or difficulty breathing symptoms arise, consult a doctor immediately. Elderly patients and those at risk of fluid volume loss should be cautious of dehydration and low blood pressure, and may need to temporarily suspend this medication if necessary. This medication can cause serious urinary infections such as urosepsis and pyelonephritis, so prompt treatment is required in the presence of infection symptoms. It is advised that pregnant or breastfeeding women do not use this medication, and administration should be discontinued if pregnancy is confirmed. Safety and efficacy in children under 18 years have not been established. During treatment, caution is necessary when driving or operating machinery due to the risk of hypoglycemia, especially when taken with insulin or sulfonylureas. Additionally, this medication may affect hydration status in the body, making it important to regularly check blood pressure and fluid status. In case of overdose, seek prompt medical attention for appropriate treatment, and keep out of reach of children.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. The recommended storage temperature is room temperature between 1 degree and 30 degrees. Proper storage helps maintain the effectiveness of the medication.
Light yellow, double-sided, convex oval film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 2L-Proline 37.8mg
Tablet · Prescription medication
Mothers Pharmaceutical Co., Ltd.

Empagliflozin 2L-Proline 15.107mg
Tablet · Prescription medication
Genewon Science Co., Ltd.

Empagliflozin 2L-Proline 37.766mg
Tablet · Prescription medication
Genewon Science Co., Ltd.

Empagliflozin 2L-Proline 15.11mg
Tablet · Prescription medication
Kyungbo Pharmaceutical Co., Ltd.

Empagliflozin 2L-Proline 37.77mg
Tablet · Prescription medication
Kyungbo Pharmaceutical Co., Ltd.

Empagliflozin 2L-Proline 15.12mg
Tablet · Prescription medication
Mothers Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.